ONCAlert | Upfront Therapy for mRCC
EGFR+ Lung Cancer: Videos
Comparing Results for 80 mg versus 160 mg Osimertinib in Advanced EGFR+ NSCLC
4:41 PM, Thu May 16, 2019
Investigating Osimertinib for Brain Activity in EGFR-Mutated Lung Cancer
8:52 PM, Tue April 16, 2019
Dr. Padda Explains the Current Role of Immunotherapy in EGFR-Mutant Lung Cancer
4:05 PM, Tue March 26, 2019
Examining Data for Osimertinib in EGFR+ Lung Cancer
5:56 PM, Fri January 25, 2019
Locally Advanced NSCLC: Next Steps in Research
12:37 PM, Fri May 18, 2018
Treating Locally Advanced NSCLC: Additional Concerns
12:37 PM, Fri May 18, 2018
Biomarkers in Locally Advanced NSCLC
12:36 PM, Fri May 18, 2018
Stage 3 Unresectable NSCLC: The PACIFIC Trial
12:36 PM, Fri May 18, 2018
